Motus GI Medical Technologies Ltd
13
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
38.5%
5 terminated/withdrawn out of 13 trials
61.5%
-25.0% vs industry average
0%
0 trials in Phase 3/4
88%
7 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Bowel Cleansing Performance of the Pure-Vu System in Patients With a History of Poor Bowel Preparation
Role: collaborator
Demonstrating Effective Salvage of Inadequate Colonoscopies
Role: lead
Clinical and Urgent Colonoscopy Outcomes Using the Pure-Vu® Cleansing System
Role: collaborator
Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System
Role: lead
Evaluation of Bowel Cleansing Using the Pure-Vu System in Patients With History of Inadequate Bowel Preparation
Role: lead
Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation
Role: lead
Evaluation of the Performance of the Motus Cleansing System (MCS)
Role: lead
Evaluation of the Performance of the Motus Cleansing System
Role: lead
Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System
Role: lead
Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System
Role: lead
Evaluation of the Performance of the CleanC System-Israel
Role: lead
Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy
Role: lead
Evaluation of the Motus GI CleanUp System During Screening Colonoscopy
Role: lead
All 13 trials loaded